Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03759340 · ClinicalTrials.gov registry record · Phase 2
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT03759340 is a Phase 2 study that was terminated before completion, run by Aclaris Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT03759340, a Phase 2 study, was terminated before completion, sponsored by Aclaris Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: * To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT following 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension. * To assess the ability of ATI-502 Topical Solution to maintain or improve hair regrowth in subjects previously treated with ATI-501 Oral Suspension or Placebo Suspension.
Interventions
- DRUG ATI 502 0.46% Topical Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03759340
The ClinicalTrials.gov registry entry for NCT03759340 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATI 502 0.46% Topical Solution is the first listed.
NCT03759340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03759340 about?
NCT03759340 is a clinical study titled "ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)". This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: * To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT following 24 weeks of treatment with ATI-501 Oral Suspension or Placebo ...
What is the current status of trial NCT03759340?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2019-01-15. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03759340?
The interventions under investigation include: ATI 502 0.46% Topical Solution (DRUG).
Who is sponsoring clinical trial NCT03759340?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.